Dublin, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The "Focal Segmental Glomerulosclerosis - Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering.
This report offers a detailed analysis of over 15 companies and 18 pipeline drugs targeting Focal Segmental Glomerulosclerosis (FSGS), a critical cause of idiopathic steroid-resistant nephrotic syndrome and end-stage kidney disease. The report examines both clinical and nonclinical stage products, focusing on product type, development stage, administration route, and molecule type. Additionally, it provides insights into inactive pipeline products in this sector.
Understanding the complex interplay contributing to podocyte injury in FSGS and acknowledging the impact of genetic mutations has guided the development of targeted therapies. Notably, mutations like NPHS2 and TRPC6 present challenges in treatment responsiveness, but do not typically recur post-kidney transplantation. Furthermore, variants in the APOL1 gene are linked to unfavorable renal prognosis and steroid resistance.
The report provides comprehensive insights into current and future prospects for FSGS treatments, covering disease overview, therapeutic guidelines, and clinical assessments of drugs in various developmental stages. It includes details on drug mechanisms, clinical studies, and regulatory activities, as well as technological developments such as collaborations, mergers, acquisitions, designations, and funding.
Emerging Drugs
- Sparsentan - Travere Therapeutics: Sparsentan, a Dual Endothelin Angiotensin Receptor Antagonist, targets endothelin A and angiotensin II subtype 1 receptors. Pre-clinical studies suggest it reduces proteinuria and protects against glomerulosclerosis. Sparsentan has orphan drug status from the FDA and EMA. As of March 2025, Travere announced an sNDA acceptance for traditional approval, with a PDUFA target date set for January 2026.
- DMX-200 - Dimerix Bioscience: DMX-200, a CCR2 blocker, is combined with standard AT1 receptor blockers. It received orphan drug designation and patents until 2032. In Phase IIa, DMX-200 showed benefits to FSGS patients, leading to its current Phase III trials.
- WAL0921 - Walden Biosciences: WAL0921, an innovative monoclonal antibody, prevents protein-induced podocyte dysfunction by targeting suPAR, a protein elevated in chronic kidney diseases. Current Phase II trials aim to validate its efficacy in halting FSGS progression.
This pipeline report categorizes drugs by development phase, administration route, molecule type, and product type. Development activities focus on innovative collaborations, licensing, and acquisitions, seeking to address unmet needs in FSGS treatment through novel drug candidates.
- Pipeline Analysis
- Therapeutic Assessment
- Impact of Drugs
- Pipeline and Therapeutic Assessments
- Key Players: Dimerix Bioscience, Travere Therapeutics, Pfizer, Goldfinch Bio
- Key Products: DMX-200, Sparsentan, PF-06730512, GFB-887
Key Topics Covered
Introduction
Executive Summary
Focal Segmental Glomerulosclerosis: Overview
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Focal Segmental Glomerulosclerosis - Analytical Perspective
Late Stage Products (Phase III)
- Comparative Analysis
DMX-200: Dimerix Bioscience
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Focal Segmental Glomerulosclerosis - Key Companies
Focal Segmental Glomerulosclerosis - Key Products
Focal Segmental Glomerulosclerosis - Unmet Needs
Focal Segmental Glomerulosclerosis - Market Drivers and Barriers
Focal Segmental Glomerulosclerosis - Future Perspectives and Conclusion
Focal Segmental Glomerulosclerosis - Analyst Views
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/6tjnak
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
